Why the study?
What is the relative potency of prostaglandin F2 alpha and 15(S)-15-methyl-PGF2 alpha on human myometrial contractility during early pregnancy?
What is the relative potency of prostaglandin F2 alpha and 15(S)-15-methyl-PGF2 alpha on human myometrial contractility during early pregnancy?
15-methyl-PGF2 alpha is significantly more potent than naturally occurring PGF2 alpha in stimulating human uterine muscle during early pregnancy.
Answers are grounded in this paper and cite their sources.
May guide prostaglandin analog dosing in early pregnancy; leaves open clinical translation and comparative trials.
The hysterometric technique has been designed to measure the pharmacological effect of active agents upon the human uterine muscle. The physiological background is the fact that smooth muscle contracts under the influence of mechanical stimulation. By applying hysterometry, the effects on the human myometrium in vivo during early pregnancy of the naturally occurring prostaglandin F2 alpha and its analogue 15(S)-15-methyl-PGF2 alpha have now been evaluated. According to the analysis of the contractile responses, the effects of the agents have been determined quantitatively. The drug effects have been characterized by changes in myometrial response between registrations under basic conditions and during the infusion of the active agent, respectively. It was found that when these drugs were given in the doses usually employed in clinical practice, the effect on contractility of the PGF2 alpha compound was more pronounced than that of the analogue. However, when describing the results on a microgram basis, the 15-methyl-PGF2 alpha was confirmed to be 10-20 times more potent than PGF2 alpha.
No takes yet. Share an insight, caveat, or question.
Jan Rydnert (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: